Matthew Biegler

Work

Analyst Matthew Biegler works at OPPENHEIMER and is focused on the Healthcare sector with 64 price targets and ratings documented since 2019 spanning on 11 stocks. Analyst's average stock valuation to be materialised ratio is 26.14% with an average time for price targets to be met of 21.38 days.

Most recent stock forecast was given on VOR, at 14-Nov-2022.

Matthew Biegler best performing recommendations are on CELU.
The best stock recommendation documented was for TPTX (TURNING POINT THERAPEUTICS, INC) at 12/8/2020. The price target of $130 was fulfilled within 13 days with a profit of $17.52 (15.58%) receiving and performance score of 11.98.

Average potential price target upside

FATE MRKR TPTX ZNTL BPMC FIXX FULC NKTX VOR CELU MDNA
FATE MRKR TPTX ZNTL BPMC FIXX FULC NKTX VOR CELU MDNA